Ironwood Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ironwood Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 922.1 times. Higher than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 65% of its market value (net debt). Lower than 93% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 922.1 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 28%
Sales fell 28% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-28% / -64%In 3 years sales changed by -28% while total assets changed by -64%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
0.6×Debt due within a year is covered 0.6 times by its yearly operating cash.
Higher than 70% of Healthcare companies in United States.
Cash Cushion Ratio
−65%Debt, after subtracting cash, equals 65% of its market value (net debt).
Lower than 93% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 92% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Ironwood Pharmaceuticals, Inc. owes $1.57 for every $1 it owns. Net profit rose 2629% in the year to Dec 2025, and shrank 48% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
4.6Investors pay $4.6 for every $1 of Ironwood Pharmaceuticals, Inc.'s yearly profit, lower than 86% of Healthcare companies in United States.
P/B ratio
-3.64Ironwood Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$590 MThe total market value of all of Ironwood Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 57% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeIronwood Pharmaceuticals, Inc.'s net worth is negative ($162 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.57×Ironwood Pharmaceuticals, Inc. owes $1.57 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Dividend yield
NoneIronwood Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
-16%Revenue fell 16% in the year to Dec 2025, and shrank 10% a year on average over 3 years.
Profit growth
+2629%Net profit rose 2629% in the year to Dec 2025, and shrank 48% a year on average over 3 years.
Profit margin
8.1%Ironwood Pharmaceuticals, Inc. keeps $8 of every $100 of revenue as net profit.
Cash quality
5.3×Cash from Ironwood Pharmaceuticals, Inc.'s business was 5.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
3.6×Ironwood Pharmaceuticals, Inc.'s operating profit covered its interest costs 3.6 times in the year to Dec 2025.
Cash vs debt
Net debtIronwood Pharmaceuticals, Inc. had $382 M more debt than cash (net debt) at Dec 2025.
Questions
What is Ironwood Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $4.6 for every $1 of Ironwood Pharmaceuticals, Inc.'s yearly profit, lower than 86% of Healthcare companies in United States.
How much does Ironwood Pharmaceuticals, Inc. owe compared with what it owns?
Ironwood Pharmaceuticals, Inc. owes $1.57 for every $1 it owns, so it owes more than it owns, higher than 95% of Healthcare companies in United States.
Does Ironwood Pharmaceuticals, Inc. pay a dividend?
No. Ironwood Pharmaceuticals, Inc. does not currently pay a dividend.
Is Ironwood Pharmaceuticals, Inc.'s revenue growing?
Revenue fell 16% in the year to Dec 2025, and shrank 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.